Journal profile · Medicine-Microbiology (medical)
Infectious Diseases and Therapy
ISSN 2193-8229 · eISSN 2193-6382 · Springer Healthcare · ENGLAND · 6 issues per year · Founded 2012
Infectious Diseases and Therapy: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.53; fully open access; APC about USD 7,675; median 62 days to acceptance (105 articles, last 24 months); 187 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Infectious Diseases and Therapy is published by Springer Healthcare and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Respiratory viral infections research, COVID-19 Clinical Research Studies and Pneumonia and Respiratory Infections, together about 24.7% of its articles. Its main subfields are Infectious Diseases. (generated from OpenAlex topic counts and CAS ranking data)
Aims and Scope Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, trial protocols, short communications such as commentaries and editorials, and letters. The journal is read by a global audience and receives submissions from around the world. Infectious Diseases and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal aims for a 2-week peer review, and 3-4 weeks from acceptance to online. Please note that for any steps outside of our standard publication processes, such as multiple rounds of peer review or article proofs, or non-standard copyright requests, this may delay publication beyond these timelines. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest rese
From the journal's Aims & Scope
Research area (LetPub): Medicine-Microbiology (medical)
Editor-in-chief Michael J. RybakPublisher website
Editorial board by country: 4 in mainland China (about 4%); most named United States 37, United Kingdom 11, Italy 10, Spain 8, Mainland China 4 (100 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Respiratory viral infections researchMedicine9.1%
- COVID-19 Clinical Research StudiesMedicine8.2%
- Pneumonia and Respiratory InfectionsMedicine7.5%
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology6.9%
- SARS-CoV-2 and COVID-19 ResearchMedicine6.3%
- Antibiotics Pharmacokinetics and EfficacyMedicine5.4%
- Antibiotic Use and ResistanceImmunology and Microbiology4.9%
- Bacterial Infections and VaccinesImmunology and Microbiology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Infectious Diseases | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Infectious Diseases | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Infectious Diseases | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCAB AbstractsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.53LetPub ·
- Impact factor (publisher) 2025
- 5.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.2Publisher website ·
- CiteScore 2026-06
- 9.3LetPub ·
- SJR 2026-06
- 1.66LetPub ·
- SNIP 2026-06
- 1.72LetPub ·
- h-index
- 76OpenAlex ·
- i10-index
- 645OpenAlex ·
- 2-year mean citedness
- 5.36OpenAlex ·
- Self-citation rate
- 5.4%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 173LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 1,400,000Publisher website ·
Articles by year OpenAlex count · 1,432 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 160 | 160 | 88 |
| 2025 | 187 | 187 | 769 |
| 2024 | 193 | 193 | 2,038 |
| 2023 | 153 | 153 | 2,693 |
| 2022 | 165 | 165 | 3,704 |
| 2021 | 199 | 199 | 5,481 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
62 daysMedian, submission to acceptance · P25–P75 38 days – 91 days
- Acceptance to online
- median 21 days (105 articles)
- Submission to online
- median 86 days
- Sample
- 105 articles with submission and acceptance dates (397 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 6 weeksLetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- Acceptance to publication
- 28 daysPublisher website ·
- Submission to publication (journal-reported)
- about 6 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 5,950 / USD 7,675 / GBP 5,120 | Yes | CC BY-NC | |
| OpenAlex | USD 7,400 / EUR 5,750 / GBP 4,900 | — | — | |
| LetPub | GBP 4,700 / USD 6,850 / EUR 5,500 | Yes | — | |
| Publisher website | EUR 5,950 / USD 7,675 / GBP 5,120 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteLicense & copyright, Open access, Peer review, Preprints
- License & copyright Copyright
Infectious Diseases and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the C…
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Infectious Diseases and Therapy, including information on fees, funding and licences, visit our Open access publishing page.
Source ↗Publisher website ·- Peer review Peer Review Process
Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and…
Source ↗Publisher website ·- Preprints Preprints
We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posti…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Healthcare
- Country or region
- ENGLAND
- Language
- English
- Frequency
- 6 issues per year
- Founded
- 2012
- ISSN
- 2193-8229
- Electronic ISSN
- 2193-6382
- Latest issue on the website
- Volume 15, Issue 10 (October 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Infectious Diseases and Therapy
What CAS zone is Infectious Diseases and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Infectious Diseases and Therapy is in Zone 2 of Medicine, and in Zone 2 of the minor category Infectious Diseases. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Infectious Diseases and Therapy?
The latest impact factor listed by LetPub is 5.53; CiteScore 9.3, h-index 76.
How long does peer review take at Infectious Diseases and Therapy?
Based on the dates recorded on 105 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 62 days (interquartile range 38–91 days); authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Infectious Diseases and Therapy based?
Of the 100 board members whose country the journal's board page names, 4 (about 4%) are in mainland China; the countries named most often are United States (37), United Kingdom (11) and Italy (10). Counted from the institutions listed on the board page; for reference only.
Which databases index Infectious Diseases and Therapy?
According to LetPub and DOAJ records, Infectious Diseases and Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase and CAB Abstracts; that list has not been checked against each database.
Is Infectious Diseases and Therapy open access, and what is the APC?
Infectious Diseases and Therapy is a fully open-access journal. APC about USD 7,675.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .